Somatuline Depot - 2007 FDA approvals

Drug: Somatuline Depot (lanreotide)
Indication: Acromegaly
Company: Biomeasure
Approval Date: August 30, 2007

Scoop: Somatuline Depot is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom those treatments are not an option. Acromegaly occurs when the pitutary gland produces excess growth hormone. The drug is available in a pre-filled syringe.

Somatuline Depot - 2007 FDA approvals
Read more on

Suggested Articles

The creation of the latest outpost of the BRIDGE model sees Evotec team up with Integra Holdings and Yissum to help researchers at Hebrew University.

Rapt Therapeutics filed to raise up to $75 million in its IPO after postponing an earlier attempt to raise $86 million in August.

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.